Immunotherapy for glioma
- 1 December 2011
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Neurology
- Vol. 24 (6) , 641-647
Abstract
During recent years different approaches have been explored to raise effective antitumor responses against brain tumors and particularly glioblastomas (GBMs). In most cases, cancer vaccines were based on autologous dendritic cells loaded with GBM peptides or whole tumor lysates. Many phase I-II studies showed that such strategy is feasible and nontoxic but failed to provide convincing evidence of its efficacy. This was due to study design and other biological issues: local immune suppression and insufficient characterization of appropriate epitopes appear as particularly relevant. In neuro-oncology intriguing data have been obtained by vaccinating patients with the epidermal growth factor receptor variant III (EGFRvIII) peptide, reproducing a specific epitope arising because of large deletion of the EGFR gene. In other cancers immunotherapy is obtaining clinically meaningful results: in prostate cancer vaccination with dendritic cells loaded with a cancer peptide, and in metastatic melanoma antibodies against an immune gate-keeper, CTL4, both led to increased survival and have been approved by FDA. On the basis of these and other clinical and preclinical findings it appears that several approaches may have chances of clinical success. They include combinatorial treatments of chemotherapy and immunotherapy, systemic and local immunotherapy, vaccination against specific targets, for example cytomegalovirus protein or stem cell markers re-expressed during brain cancer progression.Keywords
This publication has 46 references indexed in Scilit:
- Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed GlioblastomaJournal of Clinical Oncology, 2010
- Glioma Cells Display Complex Cell Surface Topographies That Resist the Actions of Cytolytic Effector LymphocytesThe Journal of Immunology, 2010
- Intralesional Lymphokine-activated Killer Cells as Adjuvant Therapy for Primary GlioblastomaJournal of Immunotherapy, 2009
- Immunotherapeutic Approaches for GliomaCritical Reviews in Immunology, 2009
- Vaccination Elicits Correlated Immune and Clinical Responses in Glioblastoma Multiforme PatientsCancer Research, 2008
- Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamicsCancer Immunology, Immunotherapy, 2007
- Dendritic Cell Vaccination in Glioblastoma Patients Induces Systemic and Intracranial T-cell Responses Modulated by the Local Central Nervous System Tumor MicroenvironmentClinical Cancer Research, 2005
- Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II TrialClinical Cancer Research, 2005
- Antitumor Vaccination of Patients With Glioblastoma Multiforme: A Pilot Study to Assess Feasibility, Safety, and Clinical BenefitJournal of Clinical Oncology, 2004
- Response criteria for phase II studies of supratentorial malignant glioma.Journal of Clinical Oncology, 1990